JP2006524190A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524190A5
JP2006524190A5 JP2006501172A JP2006501172A JP2006524190A5 JP 2006524190 A5 JP2006524190 A5 JP 2006524190A5 JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006524190 A5 JP2006524190 A5 JP 2006524190A5
Authority
JP
Japan
Prior art keywords
weight
menthol
composition
drug
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006501172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/004684 external-priority patent/WO2004073686A2/en
Publication of JP2006524190A publication Critical patent/JP2006524190A/ja
Publication of JP2006524190A5 publication Critical patent/JP2006524190A5/ja
Pending legal-status Critical Current

Links

JP2006501172A 2003-02-20 2004-02-17 薬剤のメントール溶液 Pending JP2006524190A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44924603P 2003-02-20 2003-02-20
PCT/US2004/004684 WO2004073686A2 (en) 2003-02-20 2004-02-17 Menthol solutions of drugs

Publications (2)

Publication Number Publication Date
JP2006524190A JP2006524190A (ja) 2006-10-26
JP2006524190A5 true JP2006524190A5 (enExample) 2009-12-10

Family

ID=32908699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501172A Pending JP2006524190A (ja) 2003-02-20 2004-02-17 薬剤のメントール溶液

Country Status (10)

Country Link
US (1) US20040198646A1 (enExample)
EP (1) EP1596832A2 (enExample)
JP (1) JP2006524190A (enExample)
KR (1) KR20050116368A (enExample)
CN (1) CN1882313A (enExample)
AU (1) AU2004212989A1 (enExample)
CA (1) CA2516798A1 (enExample)
EA (1) EA200501301A1 (enExample)
MX (1) MXPA05008902A (enExample)
WO (1) WO2004073686A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034920A1 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
WO2005094814A1 (ja) * 2004-03-31 2005-10-13 Kowa Co., Ltd. 外用剤
EP1720523A2 (en) * 2004-08-13 2006-11-15 Teva Pharmaceutical Industries Ltd Cyclosporin formulations
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
MX2007011858A (es) * 2005-03-30 2008-03-25 Teva Pharma Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero.
AU2006264407B2 (en) * 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
JP2022548221A (ja) * 2019-09-09 2022-11-17 テジュン ファーマシューティカル カンパニー リミテッド シクロスポリンおよびメントール含有ナノエマルジョン点眼組成物およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AU2190697A (en) * 1996-04-12 1997-11-07 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
US20010049363A1 (en) * 1998-05-08 2001-12-06 Warner-Lambert Company Oral composition containing NSAIDs and essential oils
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
DE60330322D1 (de) * 2002-03-26 2010-01-14 Teva Pharma Arzneimittel-mikroteilchen

Similar Documents

Publication Publication Date Title
US9795619B2 (en) Pharmaceutical compositions
Tiwari et al. Statins therapy: a review on conventional and novel formulation approaches
JP2006524190A5 (enExample)
CA2961528A1 (en) Long acting pharmaceutical compositions
JP2005528430A5 (enExample)
CN111867582A (zh) 衣壳组装调节剂给药方案
AU2012326976B2 (en) Sustained-release preparation
JP2004536829A (ja) セチリジン及びプソイドエフェドリンを含む錠剤
CN101932322A (zh) 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
JP2006524190A (ja) 薬剤のメントール溶液
CN1348371A (zh) 沙利度坦及其可药用的盐在制造用于治疗和预防情绪障碍、适应能力障碍或焦虑－抑郁混合病症总体上的药物方面的应用
JP2019532939A5 (enExample)
JP2007529564A5 (enExample)
KR20210137484A (ko) 캡시드 조립 조절제 고체 제형
JP2009507850A5 (enExample)
US20060141028A1 (en) Cyclosporin formulations
WO2007064083A1 (en) Spray-dried granules and processes for the preparation thereof
WO2013168179A2 (en) Controlled release pharmaceutical formulations of antiviral agents
KR20080109463A (ko) 페노피브레이트 함유 신규 조성물
AU2008200464A1 (en) Menthol solutions of drugs